Metabolic side effects of second generation antipsychotic agents in antipsychotic-naïve patients: preliminary study
Diurni, M.; Baranzini, F.; Costantini, C.; Poloni, N.; Vender, S.; Callegari, C.
Recenti Progressi in Medicina 100(2): 103
2009
ISSN/ISBN: 0034-1193 PMID: 19350804 Document Number: 636081
Document emailed within 1 workday
Related Documents
Rimón, R.; Leinonen, E. 2002: Should the second generation antipsychotic agents be used as drugs of choice? Duodecim; Laaketieteellinen Aikakauskirja 118(6): 585-590Casey, D.E. 1996: Side effect profiles of new antipsychotic agents Journal of Clinical Psychiatry 57(Suppl): 40-45; Discussion 46-52
Glaser, B.A.; Morreau, L.E. 1986: Effects of interdisciplinary team review on the use of antipsychotic agents with severely and profoundly mentally retarded persons American Journal of Mental Deficiency 90(4): 371-379
Firestone, A. 2005: Weight gain and diabetes with "second-generation" antipsychotic drugs Medical Journal of Australia 182(12): 652-653
Nightengale, B.S.; Crumly, J.M.; Liao, J.; Lawrence, B.J.; Jacobs, E.W. 1998: Economic outcomes of antipsychotic agents in a Medicaid population: traditional agents vs. risperidone Psychopharmacology Bulletin 34(3): 373-382
Gosselin, O.; Di Scala, G.; Ribeyre, J.M.; Kahn, J.P. 1996: New antipsychotic agents: new paths of research on the notion of atypical agents L'Encephale 22(Special Issue 6): 3-6
Dresse, A. 1996: Neuroleptics or antipsychotic agents Revue Medicale de Liege 51(1): 65-69
Dufresne, R.L.; Wagner, R.L. 1988: Antipsychotic-withdrawal akathisia versus antipsychotic-induced akathisia: further evidence for the existence of tardive akathisia Journal of Clinical Psychiatry 49(11): 435-438
Sami, T.; Kabadi, U.M.; Moshiri, S. 1996: The effect on metabolic control of second-generation sulfonylurea drugs in patients with NIDDM after secondary failure to first-generation agents Journal of Family Practice 43(4): 370-374
Lehtonen, J.; Tacke, U. 2003: Difficult choice between various antipsychotic agents--should we broaden our view? Duodecim; Laaketieteellinen Aikakauskirja 119(12): 1159-1162
Omori, T. 2001: Efficacy of atypical antipsychotic agents for maintenance therapy of schizophrenia Seishin Shinkeigaku Zasshi 103(6): 470-475
Roth, B.L.; Ciaranello, R.D.; Meltzer, H.Y. 1992: Binding of typical and atypical antipsychotic agents to transiently expressed 5-HT1C receptors Journal of Pharmacology and Experimental Therapeutics 260(3): 1361-1365
Gram, L.F. 2000: Malignant neuroleptic syndrome in treatment with the new, atypical antipsychotic agents, risperidone and olanzapine Ugeskrift for Laeger 162(13): 1914-1915
Sedvall, G.; Nybäck, H. 1973: Effect of clozapine and some other antipsychotic agents on synthesis and turnover of dopamine formed from 14C-tyrosine in mouse brain Israel Journal of Medical Sciences 9 Suppl: 24-30
Pugsley, T.A.; Coughenour, L.L.; Myers, S.L.; Shih, Y.H.; Courtland, G.G.; Berghoff, W.; Stewart, S.F. 1989: CI-943, a potential antipsychotic agent. II. Neurochemical effects Journal of Pharmacology and Experimental Therapeutics 251(1): 113-122
Moroharu, T.; Watanabe, N.; Ito, M. 1983: Antipsychotic effects of caerulein on chronic schizophrenia Seishin Shinkeigaku Zasshi 85(9): 611-615
Meltzer, L.T.; Christoffersen, C.L.; Heffner, T.G.; Freeman, A.S.; Chiodo, L.A. 1989: CI-943, a potential antipsychotic agent. III. Evaluation of effects on dopamine neuronal activity Journal of Pharmacology and Experimental Therapeutics 251(1): 123-130
Hong, J.S.; Yang, H.Y.; Gillin, J.C.; Costa, E. 1980: Effects of long-term administration of antipsychotic drugs on enkephalinergic neurons Advances in Biochemical Psychopharmacology 24: 223-232
Roth, B.L.; Craigo, S.C.; Choudhary, M.S.; Uluer, A.; Monsma, F.J.; Shen, Y.; Meltzer, H.Y.; Sibley, D.R. 1994: Binding of typical and atypical antipsychotic agents to 5-hydroxytryptamine-6 and 5-hydroxytryptamine-7 receptors Journal of Pharmacology and Experimental Therapeutics 268(3): 1403-1410
Read, J.; Williams, J. 2019: Positive and Negative Effects of Antipsychotic Medication: An International Online Survey of 832 Recipients Current Drug Safety 14(3): 173-181